Supplementary Material for: Chronic Kidney Disease, Circulating Ceramides and Coronary Mic

794 coronary artery disease patient records from the CRUISE-MET trial, linking chronic kidney disease and ceramide levels to coronary microvascular dysfunction. The dataset includes clinical measurements such as angiography-derived microcirculatory resistance (AMR), ceramide species profiles, and CKD classification. It was published by figshare admin karger on April 29, 2026.

Use Cases

• Analyze associations between specific ceramide species and coronary microvascular dysfunction based on AMR values.
• Investigate the combined effect of CKD and elevated ceramides on CMD prevalence based on odds ratios.
• Evaluate predictive performance of biomarkers like Cer(18:1/16:0) for CMD based on AUC and reclassification metrics.
• Perform mediation analysis to quantify the role of ceramides in the CKD-CMD pathway based on mediation percentages.

Strengths

• Includes 794 patient records from a defined clinical trial (CRUISE-MET).
• Contains specific statistical results, including correlation coefficients, odds ratios (OR=3.74), and mediation percentages (13.8%).
• Licensed under CC-BY-4.0 for open reuse.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The data files are PDF and DOCX formats, which may require extraction to access structured data.

Provenance

Source

figshare admin karger

Collection Method

Cross-sectional analysis from the CRUISE-MET trial (NCT06383208).

Freshness

Last updated 2026-04-29 05:55:12; freshness should be verified.